Hoth Submits EMA App for HT-001 Phase II Cancer Trial
September 10, 2025
Hoth Therapeutics, Inc, a biopharmaceutical company focused on creating new treatments, has submitted a Clinical Trial Application (CTA) to the European Medicines Agency (EMA) as